Use of intraoperative fluorescence to enhance robot-assisted radical prostatectomy.


Journal

Future oncology (London, England)
ISSN: 1744-8301
Titre abrégé: Future Oncol
Pays: England
ID NLM: 101256629

Informations de publication

Date de publication:
Mar 2021
Historique:
pubmed: 17 2 2021
medline: 15 10 2021
entrez: 16 2 2021
Statut: ppublish

Résumé

Robot-assisted radical prostatectomy has become the standard of care for the removal of localized prostate cancer. Positive outcomes depend upon the precise removal of the prostate and associated tissue without damage to nearby structures. This process can be aided by fluorescence-guided surgery to enhance the visual contrast between different structures. Here the authors have conducted a systematic review using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines to identify ten investigations into the use of fluorescence-guided surgery in robot-assisted radical prostatectomy. These studies used fluorescent tracers to identify structures, including the prostate, neurovascular bundle and lymph nodes. These studies demonstrate the safe and effective use of fluorescence-guided surgery in robot-assisted radical prostatectomy and pave the way for further developments in this field.

Identifiants

pubmed: 33590768
doi: 10.2217/fon-2020-0370
doi:

Substances chimiques

Fluorescent Dyes 0

Types de publication

Journal Article Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1083-1095

Subventions

Organisme : Oxford University Clinical Academic Graduate School
Organisme : Cancer Research UK
ID : C1380/A18444, C57899/A25812
Pays : United Kingdom

Auteurs

Timothy Rajakumar (T)

Department of Urology, Churchill Hospital Cancer Centre, Oxford University Hospitals NHS Foundation Trust, OX3 7LE, UK.

Musaab Yassin (M)

Department of Urology, Churchill Hospital Cancer Centre, Oxford University Hospitals NHS Foundation Trust, OX3 7LE, UK.

Omar Musbahi (O)

Department of Urology, Churchill Hospital Cancer Centre, Oxford University Hospitals NHS Foundation Trust, OX3 7LE, UK.

Eli Harris (E)

Bodleian Healthcare Libraries, University of Oxford, OX3 9DU, UK.

J Francisco Lopez (JF)

Department of Urology, Churchill Hospital Cancer Centre, Oxford University Hospitals NHS Foundation Trust, OX3 7LE, UK.

Richard J Bryant (RJ)

Department of Urology, Churchill Hospital Cancer Centre, Oxford University Hospitals NHS Foundation Trust, OX3 7LE, UK.
Nuffield Department of Surgical Sciences, University of Oxford, OX3 9DU, UK.

Iain Dc Tullis (ID)

Department of Oncology, Cancer Research UK & Medical Research Council Oxford Institute for Radiation Oncology, University of Oxford, OX3 7DQ, UK.

Borivoj Vojnovic (B)

Department of Oncology, Cancer Research UK & Medical Research Council Oxford Institute for Radiation Oncology, University of Oxford, OX3 7DQ, UK.

Freddie C Hamdy (FC)

Department of Urology, Churchill Hospital Cancer Centre, Oxford University Hospitals NHS Foundation Trust, OX3 7LE, UK.
Nuffield Department of Surgical Sciences, University of Oxford, OX3 9DU, UK.

Alastair D Lamb (AD)

Department of Urology, Churchill Hospital Cancer Centre, Oxford University Hospitals NHS Foundation Trust, OX3 7LE, UK.
Nuffield Department of Surgical Sciences, University of Oxford, OX3 9DU, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH